Published • loading... • Updated
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
- Ascletis Pharma Inc. will present multiple research posters at the 33rd European Congress on Obesity in Istanbul, Türkiye, from May 12-15, 2026.
- One poster showed Phase I data for ASC47, a thyroid hormone receptor beta agonist, which combined with semaglutide resulted in 111.8% greater weight loss than semaglutide alone in people with obesity.
- Preclinical data for ASC36, a once-monthly amylin receptor agonist, showed a 32-day half-life and 91% more weight loss than petrelintide in an obese rat model.
- ASC35, a dual GLP-1R/GIPR agonist, demonstrated a 14-day half-life and 71% more weight loss than tirzepatide in a mouse obesity model.
Insights by Ground AI
33 Articles
33 Articles
Coverage Details
Total News Sources33
Leaning Left5Leaning Right6Center12Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 22%
C 52%
R 26%
Factuality
To view factuality data please Upgrade to Premium
